文献速递眼底病与葡萄膜炎

视网膜手术中的生物材料:工程化未来

Biomaterials in Retinal Surgery: Engineering the Future.
PubMed 文献 · Am J Ophthalmol · 2026-08-30

本文为叙述性专家综述,围绕玻璃体填充剂、视网膜假体、RPE移植支架、眼内药物递送平台与基因治疗载体五个领域,梳理2018年1月至2026年3月的文献、临床试验与监管数据,并介绍作者团队的肟交联透明质酸玻璃体替代物。PRIMA光伏视网膜下植入物在32例地图样萎缩患者中26例(81%)12个月视力获临床意义改善,作者水凝胶在兔眼中保持ERG与眼压稳定。

要点

  • PRIMA视网膜下假体12个月使26/32例(81%)地图样萎缩患者视力获临床意义改善。
  • 44通道脉络膜上腔假体随访2.7年未见器械相关严重不良事件。
  • RPE支架移植已进入I/IIa期试验,抗VEGF基因治疗有3项3期试验在进行。

核心结论

  • 生物材料工程正推动视网膜疾病管理从稳定病情转向组织替代与视力恢复。
  • 主要局限是水凝胶数据仍属临床前、RPE支架试验处于早期阶段。
  • 尚存挑战包括体内长期稳定性、同种异体构造的免疫管理、可扩展制造与确证性疗效试验。

研究设计与样本

  • 叙述性专家综述,未采用系统综述方法,无方案注册、预设纳入标准、双人独立筛选或PRISMA流程图。
  • 检索PubMed/MEDLINE并补充Google Scholar,时间范围2018年1月至2026年3月,覆盖5个领域。
  • 证据来源为已发表临床前动物研究、I至III期临床试验、美国FDA批准与后节手术生物材料真实世界证据,未获取个体患者数据。
  • 作者团队的临床前水凝胶数据以原创数据形式置于综述语境中呈现。

主要发现

  • PRIMA光伏视网膜下植入物使32例地图样萎缩患者中26例(81%)在12个月时视力获临床意义改善。
  • 44通道脉络膜上腔假体在2.7年时未出现器械相关严重不良事件。
  • 作者肟交联透明质酸水凝胶密度为1.01 g/mL、折射率1.356,兔眼电生理检查保留、眼压为13.5至25.9 mmHg。
  • 基于支架的RPE移植已进入I/IIa期试验。
  • 2025年获批项目包括用于糖尿病视网膜病变的可再填充雷珠单抗端口递送系统,以及首个用于2型黄斑毛细血管扩张症的封装细胞治疗植入物。

关键数值与推荐

  • 主要结局指标包括最佳矫正视力、眼压、视网膜电图、OCT视网膜微结构、假体视力、椭圆体带面积丢失、注射频率与体内生物相容性。
  • 3项抗VEGF基因治疗3期试验正在进行中。

临床怎么用

  • 视网膜假体与RPE支架移植等生物材料手段正从稳定病情向组织替代与视力恢复拓展,可用于评估符合条件的地图样萎缩等患者。
  • 新型玻璃体替代物与长效药物递送平台有望减少注射频率,但水凝胶数据仅来自兔眼临床前研究,尚不能直接用于临床决策。
  • 关注同种异体构造的免疫管理与长期体内稳定性,是应用这些新技术前需评估的要点。

局限性

  • 水凝胶数据为作者团队临床前动物数据,尚未进入人体验证。
  • RPE支架移植试验处于I/IIa期早期阶段,疗效证据有限。
  • 本综述未采用系统综述方法,无预设纳入标准与双人独立筛选,可能存在选择偏倚。
  • 长期体内稳定性、免疫管理、规模化制造与确证性疗效试验等关键问题尚未解决。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To review current and emerging biomaterials in retinal surgery-vitreous tamponade agents, retinal prostheses, retinal pigment epithelium (RPE) transplant scaffolds, intraocular drug delivery platforms, and gene therapy vectors-with emphasis on the authors' oxime-crosslinked hyaluronic acid vitreous substitute. DESIGN: Narrative expert review. Systematic review methodology was not used; no protocol registration, prespecified eligibility criteria, dual independent screening, or PRISMA flow diagram was undertaken. SUBJECTS, PARTICIPANTS, AND/OR CONTROLS: Published preclinical animal studies, Phase I to III clinical trials, US Food and Drug Administration approvals, and real-world evidence on biomaterials in posterior segment surgery. No individual patient data were accessed. METHODS, INTERVENTION, OR TESTING: A structured literature search of PubMed/MEDLINE, supplemented by Google Scholar, was performed from January 2018 to March 2026 across 5 domains: vitreous tamponade agents; retinal prostheses; scaffold-based RPE transplantation; nanoparticle and sustained-release drug delivery; and gene therapy vectors. Peer-reviewed investigations, trial reports, and regulatory data were prioritized. The authors' preclinical hydrogel data are presented as original data within a review context. MAIN OUTCOME MEASURES: Best-corrected visual acuity, intraocular pressure, electroretinography, retinal microstructure on optical coherence tomography, prosthetic visual acuity, ellipsoid zone area loss, injection frequency, and in vivo biocompatibility. RESULTS: The PRIMA photovoltaic subretinal implant produced a clinically meaningful improvement in visual acuity in 26 of 32 patients (81%) with geographic atrophy at 12 months. A 44-channel suprachoroidal prosthesis showed no device-related serious adverse events at 2.7 years. The authors' oxime-crosslinked hyaluronic acid hydrogel demonstrated density 1.01 g/mL and refractive index 1.356, with preserved electroretinography and intraocular pressure of 13.5 to 25.9 mmHg in rabbits. Scaffold-based RPE transplantation has entered Phase I/IIa trials. 2025 approvals included a refillable ranibizumab port delivery system for diabetic retinopathy and the first encapsulated cell therapy implant for macular telangiectasia type 2. Three Phase 3 anti-VEGF gene therapy trials are ongoing. CONCLUSIONS: Biomaterial engineering is transforming retinal disease management from stabilization toward tissue replacement and vision restoration. Principal limitations are the preclinical status of the hydrogel data and early-phase status of RPE scaffold trials. Outstanding challenges include long-term in vivo stability, immunological management of allogeneic constructs, scalable manufacturing, and definitive efficacy trials.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Dindar IA, Shoichet MS, Labriola J, et al. Biomaterials in Retinal Surgery: Engineering the Future. Am J Ophthalmol. 2026. PMID: 42669344. doi:10.1016/j.ajo.2026.08.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。